Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOGEN INC.BIIB · Entity 1675 | Chief Legal Officer | September 01, 2026 | September 03, 2026 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | EVP, Chief Adm, Leg & BD Off | February 24, 2021 | February 26, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOGEN INC.
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2029-09-01 | Direct | 7,405 |
Reported balance
After 2026-09-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-01 · Grant · Acquired 7,405 · Balance 7,405 F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of September 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of September 1, 2026.
VERTEX PHARMACEUTICALS INC / MA
Report date February 24, 2021 · Filed February 26, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,837 |
Ending reported balance
After 2021-02-25 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2021-02-24 · Tax withholding · Disposed 2,416 · Balance 33,865 Row 2 · 2021-02-25 · Sale · Disposed 646 · Balance 33,219 F1: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F2: Open market sales reported on this line occurred at a weighted average price of $211.58 (range $211.34 to $211.91). F3: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Row 3 · 2021-02-25 · Sale · Disposed 1,348 · Balance 31,871 F1: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4: Open market sales reported on this line occurred at a weighted average price of $213.04 (range $212.76 to $213.68). Row 4 · 2021-02-25 · Sale · Disposed 680 · Balance 31,191 F1: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5: Open market sales reported on this line occurred at a weighted average price of $214.28 (range $213.90 to $214.69). Row 5 · 2021-02-25 · Sale · Disposed 354 · Balance 30,837 F1: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6: Open market sales reported on this line occurred at a weighted average price of $216.26 (range $215.79 to $216.76). |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $211.58 (range $211.34 to $211.91).
F3: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $213.04 (range $212.76 to $213.68).
F5: Open market sales reported on this line occurred at a weighted average price of $214.28 (range $213.90 to $214.69).
F6: Open market sales reported on this line occurred at a weighted average price of $216.26 (range $215.79 to $216.76).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2026 Filed Sep 3, 2026 20:14 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 7,405 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000082 · form4.xml · derivative · entry 1 Parini Michael · CIK 0001661567 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,405 Underlying: Common Stock · 7,405 shares Expires 2029-09-01 F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of September 1, 2026. Read SEC document |
| February 25, 2021 Filed Feb 26, 2021 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 354 | $216.26 | $76,556.04 |
DisclosureSEC source: 0001209191-21-014736 · doc4.xml · nonDerivative · entry 5 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,837 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $216.26 (range $215.79 to $216.76). Read SEC document |
| February 25, 2021 Filed Feb 26, 2021 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 680 | $214.28 | $145,710.40 |
DisclosureSEC source: 0001209191-21-014736 · doc4.xml · nonDerivative · entry 4 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,191 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $214.28 (range $213.90 to $214.69). Read SEC document |
| February 25, 2021 Filed Feb 26, 2021 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,348 | $213.04 | $287,177.92 |
DisclosureSEC source: 0001209191-21-014736 · doc4.xml · nonDerivative · entry 3 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,871 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $213.04 (range $212.76 to $213.68). Read SEC document |
| February 25, 2021 Filed Feb 26, 2021 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 646 | $211.58 | $136,680.68 |
DisclosureSEC source: 0001209191-21-014736 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,219 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $211.58 (range $211.34 to $211.91). F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 2,416 | $217.57 | $525,649.12 |
DisclosureSEC source: 0001209191-21-014736 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,865 Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $213.45 | $42,690.00 |
DisclosureSEC source: 0001209191-21-012347 · doc4.xml · nonDerivative · entry 5 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,281 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $213.45 (range $213.30 to $213.68). Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,952 | $212.56 | $414,917.12 |
DisclosureSEC source: 0001209191-21-012347 · doc4.xml · nonDerivative · entry 4 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,481 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $212.56 (range $212.25 to $212.95). Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,666 | $211.83 | $988,398.78 |
DisclosureSEC source: 0001209191-21-012347 · doc4.xml · nonDerivative · entry 3 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,433 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $211.83 (range $211.25 to $212.24). Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,007 | $210.08 | $211,550.56 |
DisclosureSEC source: 0001209191-21-012347 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,099 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $210.08 (range $209.60 to $210.54). F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 6,240 | $211.75 | $1,321,320.00 |
DisclosureSEC source: 0001209191-21-012347 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,106 Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $211.97 | $42,394.00 |
DisclosureSEC source: 0001209191-21-010703 · doc4.xml · nonDerivative · entry 3 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,346 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $211.97 (range $211.97 to $211.98). Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $211.21 | $63,363.00 |
DisclosureSEC source: 0001209191-21-010703 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,546 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $211.21 (range $210.97 to $211.33). Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,818 | $210.43 | $803,421.74 |
DisclosureSEC source: 0001209191-21-010703 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,846 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $210.43 (range $209.95 to $210.94). F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 21:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 2,563 | $214.16 | $548,892.08 |
DisclosureSEC source: 0001209191-21-010112 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,664 Read SEC document |
| February 05, 2021 Filed Feb 10, 2021 00:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock · Derivative | 1,930 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-21-009033 · doc4.xml · derivative · entry 3 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,930 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| February 05, 2021 Filed Feb 10, 2021 00:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,930 | $215.00 | $414,950.00 |
DisclosureSEC source: 0001209191-21-009033 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,227 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. Read SEC document |
| February 05, 2021 Filed Feb 10, 2021 00:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,930 | $86.52 | $166,983.60 |
DisclosureSEC source: 0001209191-21-009033 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,157 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to buy) · Derivative | 400 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-21-008132 · doc4.xml · derivative · entry 8 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,930 Underlying: Common Stock · 400 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully vested. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $218.20 | $21,820.00 |
DisclosureSEC source: 0001209191-21-008132 · doc4.xml · nonDerivative · entry 7 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,227 F4 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $217.00 | $21,700.00 |
DisclosureSEC source: 0001209191-21-008132 · doc4.xml · nonDerivative · entry 6 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,327 F4 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $215.52 | $43,104.00 |
DisclosureSEC source: 0001209191-21-008132 · doc4.xml · nonDerivative · entry 5 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,427 F4 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F5 · price: Open market sales reported on this line occurred at a weighted average price of $215.52 (range $215.47 to $215.58). F6 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 400 | $86.52 | $34,608.00 |
DisclosureSEC source: 0001209191-21-008132 · doc4.xml · nonDerivative · entry 4 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,627 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 11,627 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008132 · doc4.xml · nonDerivative · entry 3 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,227 F3 · shares: Restricted stock unit award that vests in installments beginning on 02/17/2022. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 10,324 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008132 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,600 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2021 and the shares will vest in installments beginning on 02/10/2021. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 8,438 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008132 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,276 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2018 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2021 and the shares will vest on 02/17/2021. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 21:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 25 | $224.34 | $5,608.50 |
DisclosureSEC source: 0001209191-20-059059 · doc4.xml · nonDerivative · entry 3 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,838 F1 · kind: Transaction made pursuant to Mr. Parini's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $224.34 (range $224.02 to $224.92). Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 21:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 40 | $223.67 | $8,946.80 |
DisclosureSEC source: 0001209191-20-059059 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,863 F1 · kind: Transaction made pursuant to Mr. Parini's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $223.67 (range $223.01 to $224.00). Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 21:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 26 | $222.52 | $5,785.52 |
DisclosureSEC source: 0001209191-20-059059 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,903 F1 · kind: Transaction made pursuant to Mr. Parini's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $222.52 (range $221.98 to $222.97). F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,330 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-20-057275 · doc4.xml · derivative · entry 7 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,330 Underlying: Common Stock · 2,330 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2017. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $221.25 | $44,250.00 |
DisclosureSEC source: 0001209191-20-057275 · doc4.xml · nonDerivative · entry 6 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,838 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $221.25 (range $221.09 to $221.42). Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $220.10 | $66,030.00 |
DisclosureSEC source: 0001209191-20-057275 · doc4.xml · nonDerivative · entry 5 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,038 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $220.10 (range $219.78 to $220.56). Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 600 | $218.63 | $131,178.00 |
DisclosureSEC source: 0001209191-20-057275 · doc4.xml · nonDerivative · entry 4 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,338 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $218.63 (range $218.08 to $218.95). Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 600 | $217.20 | $130,320.00 |
DisclosureSEC source: 0001209191-20-057275 · doc4.xml · nonDerivative · entry 3 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,938 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $217.20 (range $216.83 to $217.65). Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 630 | $215.16 | $135,550.80 |
DisclosureSEC source: 0001209191-20-057275 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,538 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $215.16 (range $215.00 to $215.67). F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,330 | $86.52 | $201,591.60 |
DisclosureSEC source: 0001209191-20-057275 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,168 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 20:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,223 | $0.00 Strike: $155.57 | $0.00 |
DisclosureSEC source: 0001209191-20-045939 · doc4.xml · derivative · entry 5 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,338 Underlying: Common Stock · 1,223 shares Expires 2028-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/06/2018. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 20:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 311 | $272.53 | $84,756.83 |
DisclosureSEC source: 0001209191-20-045939 · doc4.xml · nonDerivative · entry 4 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,838 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $272.53 (range $272.16 to $272.86). Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 20:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 422 | $271.45 | $114,551.90 |
DisclosureSEC source: 0001209191-20-045939 · doc4.xml · nonDerivative · entry 3 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,149 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $270.13 (range $269.73 to $270.59). F4 · price: Open market sales reported on this line occurred at a weighted average price of $271.45 (range $270.94 to $271.88). Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 20:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 490 | $270.13 | $132,363.70 |
DisclosureSEC source: 0001209191-20-045939 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,571 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $270.13 (range $269.73 to $270.59). F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 20:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,223 | $155.57 | $190,262.11 |
DisclosureSEC source: 0001209191-20-045939 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,061 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:20 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,330 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-20-045101 · doc4.xml · derivative · entry 5 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,660 Underlying: Common Stock · 2,330 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2017. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:20 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 730 | $279.41 | $203,969.30 |
DisclosureSEC source: 0001209191-20-045101 · doc4.xml · nonDerivative · entry 4 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,838 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $279.41 (range $279.03 to $279.70). Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:20 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,100 | $278.13 | $305,943.00 |
DisclosureSEC source: 0001209191-20-045101 · doc4.xml · nonDerivative · entry 3 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,568 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $278.13 (range $277.73 to $278.58). Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:20 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 500 | $276.98 | $138,490.00 |
DisclosureSEC source: 0001209191-20-045101 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,668 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $276.98 (range $276.60 to $277.39). F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:20 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,330 | $86.52 | $201,591.60 |
DisclosureSEC source: 0001209191-20-045101 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,168 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 20:41 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,125 | $0.00 Strike: $90.29 | $0.00 |
DisclosureSEC source: 0001209191-20-042488 · doc4.xml · derivative · entry 11 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,125 shares Expires 2026-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Fully vested. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 20:41 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $296.48 | $29,648.00 |
DisclosureSEC source: 0001209191-20-042488 · doc4.xml · nonDerivative · entry 10 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,838 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 20:41 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $295.38 | $88,614.00 |
DisclosureSEC source: 0001209191-20-042488 · doc4.xml · nonDerivative · entry 9 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,938 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $295.38 (range $295.16 to $295.70). Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 20:41 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 800 | $294.57 | $235,656.00 |
DisclosureSEC source: 0001209191-20-042488 · doc4.xml · nonDerivative · entry 8 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,238 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $294.57 (range $294.15 to $295.02). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.